Clinical Trial Update: Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

View source ↗

Summary

Post-marketing surveillance trial for JARDIANCE (empagliflozin) in chronic kidney disease; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Kidney Disease, Chronic | Status: ACTIVE_NOT_RECRUITING